Asia-Pacific Nebulizer Market: 2023 Study

Asia-Pacific market is estimated to grow at a CAGR of 6.6% during the forecast period (2020-2027)  to reach a market value of USD XX million by 2029.

Asia Pacific is expected to be the fastest-growing market over the forecast period owing to the large geriatric population, increasing focus on preventive care, and government initiatives promoting technological innovations. 

Developing economies, such as China and India, are attracting international players to expand their geographic reach. In May 2015, Apex Medical Corporation launched their operations in India spanning across the following product verticals, support surface, respiratory, and autoclaves. The company aims to invest around USD 15 million in the initial development phase.

This Asia Pacific  growth is driven by the continued growth of generic nebulized drugs in China, and these nebulized drugs have the largest share of the asthma and COPD market. As new drugs are developed by pharmaceutical companies, the regulatory authorities expect the drug to be registered with the nebulizer used in the pivotal trials. 

This can result in a specific drug–device combination being registered. When the drug is registered with only one device, this allows the drug packaging to be optimized for delivery with that specific device. Typically with a high-efficiency mesh nebulizer, the drug can be packaged in a 0.5–1 ml vial to suit the high efficiency of a mesh nebulizer compared with 2–5 ml required for a jet nebulizer. 

This can result in very significant cost of goods savings for the pharmaceutical company for drugs that are expensive to produce and also significant reductions in treatment time for the patient.

The adoption of mesh nebulizers as the delivery system of choice for pharmaceutical partners will continue to transform the nebulizer market as these new drugs gain marketing approval. The increased cost of the devices and the associated payment of royalties to the device manufacturers do add some additional costs to the pharmaceutical development budget, however the advantages gained for both the pharmaceutical company and the patient can bring significant overall benefits.

However, in the asthma and COPD markets where MDIs and DPIs are often the delivery system of choice, nebulizer use has been limited to patient groups such as the young and elderly who may be unable to use an MDI or DPI.

This has limited the penetration of nebulizers in the Asia Pacific markets where the current costs of delivering generic drugs is low, and developers of new formulations such as long-acting bronchodilators have initially focused on the main MDI and DPI products.

The use of a mesh nebulizer also allows pharmaceutical manufacturers to differentiate their new nebulized product from a product associated with pneumatic nebulizers, in terms of both patient benefits such as fast and silent treatments, new clinical benefits such as adherence monitoring and the ability to differentially price the product in the market.

Increase in awareness about cystic fibrosis in the region, early diagnosis of cystic fibrosis, low cost of diagnostic test, and well-established health care infrastructure in the region are likely to contribute to dominant share in the region.

Japan held the largest market share attributed to the growth of the aging population and medical care associated with it. It is anticipated that by the year 2050 around 40% of the population in Japan will grow over 65 years of age. It is prominent in Tokyo where the percentage of 65 years old population is 25% in the year 2020 and is expected to be 30% of the total population by the year 2035.

In addition, high patient awareness levels coupled with increasing healthcare expenditure and the implementation of the streamlined regulatory framework in Japan, are also driving the market in the region.

The adoption is also increasing, due to the demand for new technologies with higher quality, smaller size, lighter weight, and ease of accessibility, by the patients. Thus, the increasing demand for inhalation therapy nebulizer is driving the growth of the market in the region.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com